ENGINZYME
22.4.2020 08:02:09 CEST | Business Wire | Press release
EnginZyme, the cell-free synthetic biology company, today announced a Series A investment of €6.4 million led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, bringing the company’s total funding to over €10 million since 2014.
The funds will be used to accelerate the development of EnginZyme’s technology platform and take its first internal production process to pilot. The company also announced that Michael Krel, Partner of the Sofinnova Industrial Biotech Fund, will join EnginZyme’s Board of Directors.
“Sofinnova Partners brings a deep industrial experience, which makes them the perfect partner for us,” said EnginZyme CEO Dr. Karim Engelmark Cassimjee. “This is a complex field, so it is important to have investors that can provide not only the financial support but also strategic guidance. With over a decade of experience investing in industrial biotechnology, there are few investors as well placed as Sofinnova Partners to bring this domain expertise to the table.”
“There's never been a more important time to provide solid, long-term support to pioneering companies in industrial biotechnology,” said Michael Krel, Partner of the Sofinnova Industrial Biotech Fund. “We strongly believe in EnginZyme’s outstanding team and the potential of its technology to join the power of biology with the efficiency of chemical engineering to bring us towards a more sustainable future.”
EnginZyme seeks to solve one of the fundamental problems of our time: How to produce sustainable alternatives to plastics, nylons, rubbers, and the tons of other synthetics that are used on a daily basis, without compromising on cost-effectiveness. To achieve this, EnginZyme’s technology platform combines the breadth and power of nature (enzymatic cascades) with the efficiency of the chemical industry (packed bed reactors) in a best-of-both-worlds technical solution.
“It has long been recognized that if we could effectively access nature’s full palette of molecules, we could solve many of the world’s most pressing problems,” said Dr. Engelmark Cassimjee. “There’s just so much more you can do with biological systems than with traditional catalysts and petroleum-based building blocks. But the key word here is ‘effectively’ — it needs to be as cheap and easy to scale as the chemical solutions we’ve used for more than a century now. We’re the first company to truly address that and by doing so we are building foundational technology for an entire future industry.”
About EnginZyme
EnginZyme’s cell-free synthetic biology platform marries the efficiency of the chemical industry with the power and diversity of biology. The company was founded in Stockholm, Sweden. Since its start in 2014 it has used its technology to provide R&D services to leading companies in multiple industries, such as pharma, food, chemicals and flavors & fragrances. Its long-term aim is to make its cell-free synbio platform the foundation upon which the future chemical industry rests.
For more information, please visit: www.enginzyme.com
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies22.6.2026 22:15:00 CEST | Press release
One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced financial support via a Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop the first single-cell assay for antibody-drug conjugates (ADC) therapies in oncology. The rapid growth of ADCs is driving demand for more sophisticated biomarker strategies. By capturing tumor complexity at cellular resolution, single-cell profiling has the potential to enhance patient selection and support the development of next-generation ADCs. Ultimately, it will help match the right patients to the right therapies, maximizing therapeutic benefit. The PSCC BOOST-funded project seeks to bring a new level of precision to ADC development. It will be conducted in collaboration with Adcytherix, a clinical-stage biotech company developing differentiated ADCs for cancers with high unmet medical need. The collaboration will combine Adcytherix’s expertise in ADC development with One Biosciences’ AI-powered
Interactive Brokers Expands AI Integration Capabilities – Adding ChatGPT and Grok to Its Growing Suite of Agentic Trading Tools22.6.2026 16:00:00 CEST | Press release
Additional Asset Classes Available Including Options and Futures Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the expansion of its agentic trading capabilities with the addition of ChatGPT and Grok, further broadening a growing ecosystem of AI platform integrations that began with Claude. Available through certified AI connector marketplaces across multiple leading platforms, these integrations allow clients to research, analyze, and generate instructions with speed and efficiency to uncover new trading and investing opportunities instantly. With this release, Interactive Brokers also extends the selection of products available for order instructions to include support for options, futures and futures options in addition to equities and ETFs. “We continue to see growing interest from investors in using artificial intelligence as a more natural way to interact with financial markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “A
IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform22.6.2026 15:22:00 CEST | Press release
The collaboration will advance practical and scalable hybrid classical-quantum applications. This follows IQM's first on-premises quantum computer installation in the United States, at Oak Ridge National Laboratory. IQM has sold 23 quantum systems globally to date and intends to list on Nasdaq in the United States by mid 2026. Hewlett Packard Enterprise has named IQM Quantum Computers among the companies collaborating on its hybrid classical-quantum computing platform, announced at HPE Discover Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622035759/en/ IQM Radiance quantum computer at HPE Discover Las Vegas 2026 IQM, a global leader in full-stack superconducting quantum computers, is contributing superconducting quantum processor technology to the effort, in which HPE is integrating multiple quantum modalities with its Cray supercomputing infrastructure. This collaboration strengthens IQM's global expansion p
Return Abuse Goes Mainstream as Nearly Half of Consumers Use AI in Return Claims, New Riskified Research Finds22.6.2026 14:30:00 CEST | Press release
New global study shows normalization of strategic returns, widening regional differences, and rapid AI adoption reshaping ecommerce post-purchase risk Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today released a new global report, “Rewriting the Rules on Returns”, exploring how consumer attitudes and behaviors around ecommerce returns are evolving in the age of artificial intelligence (AI). The Riskified-commissioned study, conducted by eTail Insights, is based on a survey of 2,091 consumers across seven countries, alongside in-depth interviews with senior leaders from many of the largest retail companies in the world. The research finds that return abuse behaviors are increasingly normalized, while nearly half of consumers already use generative AI tools to assist with return or refund claims. At the same time, merchants are responding by tightening return policies, shortening return windows, and deploying advanced AI detection to better
Forrester Unveils Agendas For 2026 Technology & Innovation Forums In North America And EMEA22.6.2026 14:00:00 CEST | Press release
The Forums will equip technology leaders with the capabilities needed to operationalize AI and build high-performing IT organizations that deliver measurable business outcomes Forrester (Nasdaq: FORR) today announced the full conference agendas for its Technology & Innovation Forum Central (Austin, September 14–15, 2026), Technology & Innovation Forum EMEA (London, September 30–October 1, 2026), and Technology & Innovation Forum East (New York City, November 4–5, 2026). This year’s theme, “The IT Singularity,” dives into the new AI era in which AI has become ubiquitous and no longer a competitive advantage on its own. To succeed, technology leaders including chief information officers, chief data officers, and chief AI officers need to integrate AI into their operating models, modernize software development and IT operations, strengthen data and governance practices, and align technology investments with business strategy. Across the Forums, tech leaders and their teams will learn how
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom